<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04133896</url>
  </required_header>
  <id_info>
    <org_study_id>Obesity and IR</org_study_id>
    <nct_id>NCT04133896</nct_id>
  </id_info>
  <brief_title>Circulating IL-6, Clusterin and Irisin in Obese Subjects</brief_title>
  <official_title>Circulating IL-6, Clusterin and Irisin in Obese Subjects With Different Grades of Obesity: Association With Insulin Resistance and Sexual Dimorphism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rehab Werida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damanhour University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      evaluate the circulating levels of IL-6, clusterin and irisin in obese subjects of both sexes
      who had different classes of obesity and their sexual dimorphism also identify the
      association of IL-6, clusterin and irisin with insulin resistance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim: Firstly, this study aimed at assessing the circulating levels of IL-6, clusterin and
      irisin in obese subjects of both sexes who had different classes of obesity and evaluating
      their sexual dimorphism and secondly evaluate the association of IL-6, clusterin and irisin
      with insulin resistance.

      Method: This study was conducted on 176 non-diabetic subjects of both sexes. Participants
      were classified according to their sex into two groups; the male and female groups. The male
      group (88 men) was classified according to BMI into; group 1 (22 lean men), group 2 (22 class
      I obese men), group 3 (22 class II obese men), and group 4 (22 class III obese men). The
      female group (88 women) was also classified according to BMI exactly as the male group.
      Fasting blood glucose, fasting insulin, lipid panel, serum IL-6, clusterin and irisin levels
      were measured. One-way analysis of variance followed by Tukey's as post hoc test was used for
      comparison of variables.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Actual">June 30, 2019</completion_date>
  <primary_completion_date type="Actual">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>insulin resistance</measure>
    <time_frame>18 months</time_frame>
    <description>by homeostasis insulin resistance index (fasting insulin (Î¼IU/ml) times fasting glucose (mg/L) divided by 405 )</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL- 6</measure>
    <time_frame>18 Months</time_frame>
    <description>blood level of IL-6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clusterin</measure>
    <time_frame>18 Months</time_frame>
    <description>blood level of Clusterin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Irisin</measure>
    <time_frame>18 Months</time_frame>
    <description>blood level of Irisin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>18 Months</time_frame>
    <description>Plasma triglycerides and total cholesterol were measured by enzymatic colorimetric method. High-density lipoprotein cholesterol (HDL-C) was measured by precipitation method. Low density lipoprotein cholesterol (LDL-C) was calculated using the Friedewald formula</description>
  </primary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Actual">176</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group 1 Male</arm_group_label>
    <description>group 1 (22 lean men),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Male</arm_group_label>
    <description>group 2 (22 class I obese men),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Male</arm_group_label>
    <description>group 3 (22class II obese men),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Male</arm_group_label>
    <description>group 4 (22 class III obese men).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1 Female</arm_group_label>
    <description>group 1 (22 lean women),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Female</arm_group_label>
    <description>group 2 (22 class I obese women),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 Female</arm_group_label>
    <description>group 3 (22 class II obese women),</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4 Female</arm_group_label>
    <description>group 4 (22 class III obese women).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>IL-6, Clusterin, Irisin Level</intervention_name>
    <description>Blood samples to determine levels of Circulating IL-6, Clusterin and Irisin</description>
    <arm_group_label>Group 1 Female</arm_group_label>
    <arm_group_label>Group 1 Male</arm_group_label>
    <arm_group_label>Group 2 Female</arm_group_label>
    <arm_group_label>Group 2 Male</arm_group_label>
    <arm_group_label>Group 3 Female</arm_group_label>
    <arm_group_label>Group 3 Male</arm_group_label>
    <arm_group_label>Group 4 Female</arm_group_label>
    <arm_group_label>Group 4 Male</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects included in the study were classified according to their sex into two main group
        the male group and the female group. The male group contained 88 men which subdivided
        according to the BMI into the following groups; group 1 (22 lean men), group 2 (22 class I
        obese men), group 3 (22class II obese men), and group 4 (22 class III obese men). The
        female group contained 88 adult women which sub-classified according to BMI into the
        following subgroups; group 1 (22 lean women), group 2 (22 class I obese women), group 3 (22
        class II obese women), and group 4 (22 class III obese women).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Female and Male

          -  Age matched adult non-diabetic non-smoker males and females'

        Exclusion Criteria:

          -  smokers, subjects with a history of diabetes mellitus, liver, renal, thyroid,
             inflammatory diseases, and females on contraceptives pills. Patients on medications
             that can interfere with glucose or lipid metabolism (corticosteroids,
             anti-hyperlipidemics, non-selective beta blockers, thiazides, etc.) and subjects with
             organic causes of obesity were also excluded from this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>based on self-representation of gender identity.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rehab H Werida, Lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damanhour University, Faculty of Pharmacy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>El-Gharbia</state>
        <zip>31527</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <results_reference>
    <citation>Gouni-Berthold I, Berthold HK, Huh JY, Berman R, Spenrath N, Krone W, Mantzoros CS. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo. PLoS One. 2013 Sep 2;8(9):e72858. doi: 10.1371/journal.pone.0072858. eCollection 2013.</citation>
    <PMID>24023786</PMID>
  </results_reference>
  <results_reference>
    <citation>Baralla A, Sotgiu E, Deiana M, Pasella S, Pinna S, Mannu A, Canu E, Sotgiu G, Ganau A, Zinellu A, Sotgia S, Carru C, Deiana L. Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians. PLoS One. 2015 Jun 15;10(6):e0128029. doi: 10.1371/journal.pone.0128029. eCollection 2015.</citation>
    <PMID>26076476</PMID>
  </results_reference>
  <results_reference>
    <citation>van Greevenbroek MM, Schalkwijk CG, Stehouwer CD. Obesity-associated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med. 2013 May;71(4):174-87. Review.</citation>
    <PMID>23723111</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 18, 2019</study_first_submitted>
  <study_first_submitted_qc>October 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 21, 2019</study_first_posted>
  <last_update_submitted>October 19, 2019</last_update_submitted>
  <last_update_submitted_qc>October 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Damanhour University</investigator_affiliation>
    <investigator_full_name>Rehab Werida</investigator_full_name>
    <investigator_title>Clinical Pharmacy Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

